Altera Digital Health and Pipeline Health Extend Partnership by Seven Years

Altera Digital Health, a global healthcare IT innovator, today announced it has expanded its partnership with Pipeline Health, a community-based hospital system headquartered in Los Angeles. The seven-year contract will extend Pipeline Health’s use of the Paragon electronic health record (EHR) at four…

Read MoreAltera Digital Health and Pipeline Health Extend Partnership by Seven Years

Vivasure Medical Announces Enrollment of First Patients in Pivotal PATCH Study

a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced it has enrolled the first patients in the company’s PerQseal® PATCH Clinical Study, a multi-center, single-arm, pivotal study evaluating the safety and efficacy of the Vivasure PerQseal Closure…

Read MoreVivasure Medical Announces Enrollment of First Patients in Pivotal PATCH Study

Global mRNA Synthesis Raw Materials Market Report 2023: Increasing Funding For mRNA Research Drives Growth – ResearchAndMarkets.com

The global mRNA synthesis raw materials market size is projected to reach USD 3.3 billion by 2030. The market is expected to expand at a CAGR of 2.1% from 2023 to 2030. The major factors driving the market growth include…

Read MoreGlobal mRNA Synthesis Raw Materials Market Report 2023: Increasing Funding For mRNA Research Drives Growth – ResearchAndMarkets.com

Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious Diseases

Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA) focused on delivering innovative therapies in critical care and infectious disease, today announced that The Lancet Infectious Diseases published detailed results from the pivotal Phase 3 ATTACK trial of sulbactam-durlobactam, the first…

Read MoreResults from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious Diseases

Navidea Biopharmaceuticals, Inc. Promotes Michael Sherman Blue, M.D., FACEP, to Chief Medical Officer

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the promotion of Michael Sherman Blue, M.D., FACEP to the position of Chief Medical Officer (CMO),…

Read MoreNavidea Biopharmaceuticals, Inc. Promotes Michael Sherman Blue, M.D., FACEP, to Chief Medical Officer

Scientist.com erwirbt Labs Explorer und führt schnelle Expansion in den europäischen Forschungsmarkt fort

Scientist.com, der führende Marktplatz für präklinische Forschung für den biopharmazeutischen Sektor, gab heute die kürzliche Übernahme von Labs Explorer bekannt, einem bekannten französischen Netzwerk, das europäische Forschungslabore, wissenschaftliche Fachleute und innovative Start-ups miteinander verbindet. Dieser strategische Schritt verschafft den Nutzern…

Read MoreScientist.com erwirbt Labs Explorer und führt schnelle Expansion in den europäischen Forschungsmarkt fort

Lineage Cell Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the first quarter ended March 31, 2023 and will host a conference call today at 4:30 p.m. Eastern Time to discuss…

Read MoreLineage Cell Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

Equillium Reports First Quarter 2023 Financial Results and Provides Clinical Updates

 a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the first quarter 2023 and provided corporate and clinical…

Read MoreEquillium Reports First Quarter 2023 Financial Results and Provides Clinical Updates